Trade Verve Therapeutics, Inc. - VERV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.14 |
| Open | 5.11 |
| 1-Year Change | -64.17% |
| Day's Range | 5.11 - 5.72 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 5.72 | 0.62 | 12.16% | 5.10 | 5.74 | 5.08 |
| Dec 19, 2024 | 5.14 | 0.05 | 0.98% | 5.09 | 5.22 | 4.86 |
| Dec 18, 2024 | 5.06 | -0.49 | -8.83% | 5.55 | 5.55 | 5.03 |
| Dec 17, 2024 | 5.59 | 0.25 | 4.68% | 5.34 | 5.68 | 5.21 |
| Dec 16, 2024 | 5.38 | -0.29 | -5.11% | 5.67 | 5.68 | 5.16 |
| Dec 13, 2024 | 5.68 | -0.36 | -5.96% | 6.04 | 6.06 | 5.43 |
| Dec 12, 2024 | 6.20 | -0.10 | -1.59% | 6.30 | 6.30 | 6.01 |
| Dec 11, 2024 | 6.29 | -0.39 | -5.84% | 6.68 | 6.68 | 6.05 |
| Dec 10, 2024 | 6.69 | -0.40 | -5.64% | 7.09 | 7.14 | 6.61 |
| Dec 9, 2024 | 7.16 | 0.64 | 9.82% | 6.52 | 7.37 | 6.51 |
| Dec 6, 2024 | 6.44 | 0.34 | 5.57% | 6.10 | 6.66 | 6.02 |
| Dec 5, 2024 | 6.08 | -0.47 | -7.18% | 6.55 | 6.55 | 5.95 |
| Dec 4, 2024 | 6.59 | -0.48 | -6.79% | 7.07 | 7.35 | 6.55 |
| Dec 3, 2024 | 6.98 | -0.12 | -1.69% | 7.10 | 7.63 | 6.89 |
| Dec 2, 2024 | 7.12 | 1.50 | 26.69% | 5.62 | 7.26 | 5.51 |
| Nov 29, 2024 | 5.59 | -0.18 | -3.12% | 5.77 | 5.81 | 5.54 |
| Nov 27, 2024 | 5.75 | 0.47 | 8.90% | 5.28 | 5.84 | 5.28 |
| Nov 26, 2024 | 5.28 | 0.02 | 0.38% | 5.26 | 5.30 | 5.06 |
| Nov 25, 2024 | 5.25 | 0.34 | 6.92% | 4.91 | 5.45 | 4.91 |
| Nov 22, 2024 | 4.82 | 0.32 | 7.11% | 4.50 | 4.84 | 4.50 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Verve Therapeutics, Inc. Company profile
About Verve Therapeutics Inc
Verve Therapeutics, Inc. is a genetic medicines company. The Company is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. It is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The Company's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The Company's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Verve Therapeutics Inc revenues was not reported. Net loss increased from $45.7M to $120.3M. Higher net loss reflects Fair Value of antidilution rights increase from $5.4M to $25.6M (expense), Fair Value Adjustment of success payment increase from $2.4M to $7.8M (expense), Interest Income - Non Bank decrease of 12% to $142K (income).
| Industry: | Biotechnology & Medical Research (NEC) |
201 Brookline Avenue
Suite 601
BOSTON
MASSACHUSETTS 02215
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com